Celanese Presents Advancements in Pharmaceutical Controlled Release at Polymers in Medicine and Biology Conference
By Business Wire News
By Business Wire News
Celanese Corporation (NYSE: CE), a global technology and specialty materials company, will present its industry-leading innovation in pharmaceutical, controlled release ethylene vinyl acetate (EVA) copolymersat the Polymers in Medicine and Biology Conference, September 14-17 in Santa Rosa, Calif.
Celanese materials experts will discuss the challenges of developing and commercializing new innovations while trying to meet ever-changing regulatory requirements. And building upon clinically-approved materials technology, Celanese will discuss how it is helping to find middle ground and expand drug product technology.
“Our pharmaceutical EVA, VitalDose®, is a proven, controlled-release excipient that has been clinically approved in drug delivery systems for many years,” said Jose Reyes, strategic marketing manager. “New dosage forms, such as the foamed excipient, are changing the way new therapies and biologics could be delivered to the body and are offering new dimensions for immunogenic mitigation possibilities through the material’s customizable release profile capabilities.”
“Celanese collaborates with many early-stage investigators conducting the essential research into the improvement of human health using devices, drug products and systems that address chronic needs in metabolic disease, cancer, addiction, infection, women’s health, and combination therapies, among others,” said Don Loveday, strategic marketing manager.
Celanese presentation sessions:
- Jose Reyes will present “Solving the Medical Polymers Paradox with Ethylene Vinyl Acetate Copolymers for Enabling Advanced Delivery of Proteins and Stem Cells” on Tuesday, September 15, 2015 at 9:00 a.m.
- Don Loveday will lead the Entrepreneurship sessions on Wednesday, September 16, from 3:00 p.m. to 5:45 p.m., featuring presentations from ExThera, Google, Healionics, and Profusa, among others.
For more information about Celanese’s controlled release pharmaceutical EVA, VitalDose®, visit www.vitaldose.com.
Celanese Corporation is a global technology leader in the production of differentiated chemistry solutions and specialty materials used in most major industries and consumer applications. With sales almost equally divided between North America, Europe and Asia, the company uses the full breadth of its global chemistry, technology and business expertise to create value for customers and the corporation. Celanese partners with customers to solve their most critical needs while making a positive impact on its communities and the world. Based in Dallas, Texas, Celanese employs approximately 7,500 employees worldwide and had 2014 net sales of $6.8 billion. For more information about Celanese Corporation and its product offerings, visit www.celanese.com or our blog at www.celaneseblog.com.
All registered trademarks are owned by Celanese International Corporation or its affiliates.
This release may contain “forward-looking statements,” which include information concerning the company’s plans, objectives, goals, strategies, future revenues or performance, capital expenditures, financing needs and other information that is not historical information. When used in this release, the words “outlook,” “forecast,” “estimates,” “expects,” “anticipates,” “projects,” “plans,” “intends,” “believes,” and variations of such words or similar expressions are intended to identify forward-looking statements. All forward-looking statements are based upon current expectations and beliefs and various assumptions. There can be no assurance that the company will realize these expectations or that these beliefs will prove correct. There are a number of risks and uncertainties that could cause actual results to differ materially from the forward-looking statements contained in this release. Numerous factors, many of which are beyond the company’s control, could cause actual results to differ materially from those expressed as forward-looking statements. These factors include the inability to obtain regulatory approvals of the transaction and satisfy conditions on the proposed terms and schedule and the possibility that the transaction does not close. Other risk factors include those that are discussed in the company’s filings with the Securities and Exchange Commission. Any forward-looking statement speaks only as of the date on which it is made, and the company undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date on which it is made or to reflect the occurrence of anticipated or unanticipated events or circumstances.